Canada

ZYUS Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production

Lead Product(s): Plant-based COVID-19 antigen

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

Preliminary research results from ZYUS Life Sciences show that plant-based antigens are reactive to anti-COVID-19 antibodies and potentially offer immunity from COVID-19.

AbCellera

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly

Lead Product(s): Antibodies

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 22, 2020

Details:

AbCellera will use its world-leading antibody drug discovery platform in a multi-year collaboration to identify antibodies against up to nine targets.

IMV

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations

Lead Product(s): DPX-COVID-19

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

The Company has used sequences of the virus and immunoinformatics to predict and has identified 23 epitopes for their potential to generate neutralizing antibodies against SARS-CoV-2.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

ZYUS Life Sciences

ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production

AbCellera

AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly

IMV

IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations